Navigation Links
Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
Date:3/7/2008

SAN DIEGO, March 7 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today announced that it will release financial results for the three and twelve months ended December 31, 2007 after market close on Thursday, March 13, 2008.

Jonathan Lim, MD, President and Chief Executive Officer, Gregory Frost, PhD, Vice President and Chief Scientific Officer, Robert Little, Vice President and Chief Commercial Officer, and David Ramsay, Vice President and Chief Financial Officer, will host an investment community conference call beginning at 8:00 a.m. PT (11:00 a.m. ET) on Friday, March 14, 2008, to provide a pipeline update.

Individuals interested in participating in the conference call may do so by dialing 888-256-9044 for domestic callers or 706-643-5585 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the Company's web site at http://www.halozyme.com. A replay will be available on Halozyme's web site for 30 days. A telephone replay will be available for 48 hours by dialing 800-642-1687 from the U.S., or 706-645-9291 for international callers, and entering reservation code 38622372.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products based on the extracellular matrix for the drug delivery, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The co
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
2. Halozyme Therapeutics Amends Stockholder Rights Plan
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
5. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
6. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
7. ExonHit Therapeutics - 2007 Financial Results
8. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
9. Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
10. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
11. CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... August 22, 2014 “Our nation's ... is a national disgrace. Furthermore, every governmental and ... the current, deplorable state of unorganized dysfunction shares ... mistakes," to merely serve as a device to ... of colossal failure(s) that have accumulated through the ...
(Date:8/21/2014)...  BioSpecifics Technologies Corp. (NASDAQ: BSTC ... collagenase-based products marketed as XIAFLEX ® (collagenase ... XIAPEX ® in the EU, today announced ... Phase 2a study of CCH for the potential ... results showed that all three doses of CCH ...
(Date:8/21/2014)... Rockville, MD (PRWEB) August 21, 2014 ... is making progress in its development of JRC-LAMP-vax, an ... red cedar pollen. Phase IC studies began this month ... solution to hay fever. , The Japanese red cedar ... million people in Japan. Mountain Cedar pollen wreaks similar ...
(Date:8/21/2014)... group at the Institute for Molecular Medicine Finland ... has developed a novel "man and machine" decision ... diagnostic aid was described in PLOS One ... is based on computer vision algorithms similar to ... visualization of only the diagnostically most relevant areas. ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4A novel 'man and machine' decision support system makes malaria diagnostics more effective 2
... in German . , The polymer ... expected about 30 scientists to attend the kick-off meeting ... for Carbon-based Nanocomposites). New kinds of plastic-based nanocomposites could ... the mechanical stability of materials and add electrical or ...
... a Rochester, NY company today announced it is bringing aboard Ashton ... to head up global sales and marketing. , ... ... company today announced it is bringing aboard Ashton S. Maaraba, a ...
... a biopharmaceutical company specializing in the research and,development of ... reported financial results for the three and twelve months,ended ... in Canadian,dollars., 2008 HIGHLIGHTS, - ... anticancer small molecule drug ...
Cached Biology Technology:Using nanotechnology to create high-performance materials 2Pharmasmart International Taps Top Executive Ashton Maaraba to Head Global Sales and Marketing 2Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 2Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 3Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 4Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 5Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 6Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 7Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 8
(Date:8/22/2014)... be able to purchase fuel cell cars from Toyota ... of the cars will run on hydrogen made from ... warming. , Now scientists at Stanford University have developed ... battery to produce hydrogen by water electrolysis. The ... split liquid water into hydrogen and oxygen gas. Unlike ...
(Date:8/22/2014)... the bees. But that old expression leaves out ... process for flowering plants is particularly complex and ... reproductive cells. New research from an international team ... Carnegie,s Wolf Frommer, David Ehrhardt, and Guido Grossmann ... guides flowering plant fertilization. It is published in ...
(Date:8/21/2014)... international team of scientists including researchers from the University of ... known as canolain the journal Science . Their discovery ... is used widely in farming and industry. , Canola ... but the winter crop is increasingly cultivated in Georgia. Canola ... levels of saturated fat and rich supply of omega-3 fatty ...
Breaking Biology News(10 mins):Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Calcium and reproduction go together 2Canola genome sequence reveals evolutionary 'love triangle' 2
... Since the smoking ban in restaurants, bars and ... as body odors and the smell of old beer, ... science is looking at how the introduction of pleasant ... nightlife experience. According to Dr. Hendrik Schifferstein from Delft ...
... River and its tributaries, is the largest contiguous wetland in ... it is an ark for large populations of species that ... large range of ecosystem services that are essential for humanity. ... plants, animals, and local human populations show an impressive range ...
... organ-on-a-chip devices that mimic the way real organs work, ... of therapies more accurately, will be discussed by a ... Professor Don Ingber, Director of the Wyss ... deliver the inaugural Bagrit Lecture, which will be held ...
Cached Biology News:Clubbers can smell a good nightspot 2Media invitation: Pioneer of organ-on-a-chip technology to speak at Imperial College London 2
...
... camera controller is the successor to the original ... any of the cameras in the Nikon DS ... USB2.0 interface. The DS-U2 transmits information at high ... equipping both hub and mass storage USB 2.0 ...
This unique buffer provides a gentle method for removal of primary and secondary antibodies to allow several reprobings on the same membrane. Gentle buffer will not alter the antigen for subsequent i...
...
Biology Products: